financetom
Business
financetom
/
Business
/
PNB moves court seeking restoration of assets of Nirav Modi's firms confiscated by ED
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
PNB moves court seeking restoration of assets of Nirav Modi's firms confiscated by ED
Jul 14, 2021 1:25 PM

The Punjab National Bank (PNB) on Wednesday moved multiple applications before a special PMLA court here, seeking restoration of the assets of two firms owned by fugitive diamond merchant Nirav Modi, who is accused of duping the bank. The bank submitted the applications before special judge V C Barde under the relevant provisions of the Prevention of Money Laundering Act (PMLA).

Share Market Live

NSE

The Enforcement Directorate (ED) had earlier confiscated assets worth over Rs 329.66 crore of Nirav Modi under the fugitive economic offenders law. The confisticated property includes assets of Firestar Diamond International Private Limited and Firestar International Limited, firms owned by Modi.

Nirav Modi and his uncle Mehul Choksi, both prime accused in the case, along with others are being probed by the Enforcement Directorate (ED) on money laundering charges for allegedly perpetrating an over USD 2 billion (more than Rs 13,000 crore) bank fraud in connivance with bank officials and by issuance of fraudulent Letters of Undertaking (LoUs) at the Brady House PNB branch in Mumbai.

The court has asked the ED to file its reply on July 28. Nirav Modi (49) was declared a fugitive economic offender by the PMLA court in December 2019. Following that, the court had authorised the ED to confiscate the assets under the provisions of the Act. He is currently lodged in a UK jail after being arrested in London in March, 2019 and is currently fighting extradition to India.

First Published:Jul 14, 2021 10:25 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges
Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges
Dec 19, 2024
On Thursday, Omeros Corporation ( OMER ) announced that an independent statistical group has completed the primary statistical analysis agreed with the FDA for narsoplimab. Omeros ( OMER ) is a first-in-class monoclonal antibody that inhibits the lectin pathway of complement in hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). TA-TMA is a complication in adult and pediatric hematopoietic stem cell...
--Guaranty Bancshares Keeps Quarterly Dividend at $0.24 a Share, Payable Jan. 8 to Shareholders of Record Dec. 30
--Guaranty Bancshares Keeps Quarterly Dividend at $0.24 a Share, Payable Jan. 8 to Shareholders of Record Dec. 30
Dec 19, 2024
12:25 PM EST, 12/19/2024 (MT Newswires) -- Price: 34.35, Change: -0.03, Percent Change: -0.09 ...
Legal Fee Tracker: Settlements spur big fee awards, with more to come in 2025
Legal Fee Tracker: Settlements spur big fee awards, with more to come in 2025
Dec 19, 2024
Dec 19 (Reuters) - U.S. courts awarded hundreds of millions of dollars in legal fees to class action lawyers and other attorneys in 2024, with hundreds of millions more still hanging in the balance in 2025. Here are some of the largest awards and outstanding fee bids heading into the new year. - Two of the biggest attorney paydays of...
Bio-Path Holdings Shares Were On The Rise: What's Going On?
Bio-Path Holdings Shares Were On The Rise: What's Going On?
Dec 19, 2024
Bio-Path Holdings, Inc ( BPTH ). shares are surging Thursday following the company's announcement of encouraging preclinical results for BP1001-A, a potential treatment for obesity and Type 2 diabetes. Here’s what you need to know. What To Know: The preclinical studies demonstrated that BP1001-A enhances insulin sensitivity by downregulating the growth factor receptor-bound protein 2. These findings suggest BP1001-A could...
Copyright 2023-2026 - www.financetom.com All Rights Reserved